English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
The DEA vs. Ayahuasca: How a Flawed Federal Report Tried to Reshape the Conversation
Somewhere in a federal filing cabinet sat a document the public wasn't supposed to see for a long time. It took two Freedom of Information Act requests and the better part of two years before the DEA finally handed it over — a report titled Ayahuasca: Risks to Public Health and Safety, dated July 2020. Once it surfaced, the scientific community read it, raised eyebrows, and then sharpened their pens. If you're researching ayahuasca seriously — maybe weighing a retreat in Peru, maybe wondering whether the legal grey zone in the U.S. is shifting — this story matters. It tells you a lot about why ayahuasca occupies the strange position it does in American law, why research has been so slow despite mounting evidence of therapeutic benefit, and why the regulatory landscape isn't likely to shift overnight. Knowing this context changes how you think about plant medicine, about master plants, and about the whole machinery surrounding psychedelics and addiction recovery in the West. The report came out of an internal DEA review and landed firmly on the prohibitionist side of the ledger. Its core claim: ayahuasca poses a meaningful risk to public health and safety. That framing matters because it props up the federal classification of DMT — the active alkaloid in the brew — as a Schedule I substance. Schedule I, in DEA parlance, means a drug with high abuse potential and no accepted medical use. The agency has long argued that ayahuasca is essentially a delivery vehicle for DMT, which is how it justifies the same legal treatment. The trouble is, the report leaned heavily on a curated stack of references that supported its conclusions while leaving out a striking amount of contrary evidence. There was no mention, for instance, of the first randomized controlled trial of ayahuasca for treatment-resistant depression — a study that suggested both reasonable tolerability and meaningful clinical benefit. There was scant engagement with decades of epidemiological data from Indigenous Amazonian communities and the Brazilian religious churches (Santo Daime, União do Vegetal) where ayahuasca has been consumed ceremonially for generations without the public-health catastrophe the agency seems to anticipate. In other words: the science was selective. Not absent, just trimmed. In June 2023, the Chacruna Institute — together with scholars across biology, neuroscience, psychiatry, anthropology, and sociology — published a formal critique in the Journal of Psychedelic Studies. The article walked through the DEA report point by point, documenting factual omissions, theoretical assumptions presented as established fact, and what looked an awful lot like confirmation bias dressed up in citations. A few of the rebuttal's sharpest threads: The point of the critique wasn't to declare ayahuasca a miracle cure. It was to insist that policy this consequential should rest on a complete reading of the evidence, not a partial one. Here's where the abstract policy fight touches the ground. If you're a person in the U.S. researching ayahuasca because nothing else has worked for your depression, your drinking, your PTSD — the federal stance on plant medicine is a big part of why you're probably looking at a retreat in Peru, Costa Rica, or Brazil rather than a clinic in Colorado. The Schedule I classification creates real downstream effects. Research funding is harder to secure. Clinical trials face procedural hurdles that drugs in other categories don't. Therapists who might otherwise help with integration work risk their licenses if they get too close to the substance itself. And practitioners who run ceremonies in the U.S. — outside the narrow religious exemptions granted to the UDV in 2006 and to Santo Daime shortly after — operate in legal jeopardy. That's the landscape you're navigating when you start comparing retreat centers. The retreat industry that's grown up in Latin America exists in part because of these federal blockages. Many facilitators are themselves U.S. expats who relocated precisely because they couldn't practice openly at home. Short answer: not soon. The agency's mandate is enforcement, not research advocacy. Drug scheduling decisions technically flow from a coordinated process involving the FDA, but the DEA has historically resisted descheduling petitions even when the underlying science had moved on. The most-cited example is cannabis — twenty-five-plus years of state-level legalization, mounting clinical data, and federal scheduling has barely budged. A few realistic paths forward, in rough order of likelihood: For now, the gap between what the research suggests about plant medicine and addiction recovery — and what U.S. policy permits — remains wide. The Chacruna rebuttal won't close it by itself, but it's the kind of scholarship that eventually changes minds in the rooms where these decisions get made. If you've read this far, you're the kind of person who wants to make an informed decision rather than just chase a transformative-sounding weekend. A few honest pointers, born out of the policy reality above: The DEA's report tried to flatten a complex picture into a single warning label. The peer-reviewed response did the harder work of holding multiple truths at once: yes, there are risks; yes, there is therapeutic promise; yes, the science deserves better than selective citation. That's the spirit you want to bring to your own research, too. If something in this piece resonates and you're ready to look at the practical side of things, a curated selection of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — the medicine isn't going anywhere, and the right setting matters more than the calendar does.
Synthetic Psilocybin and the Pharma Race to Medicalize Magic Mushrooms
Somewhere right now, in a quiet clinical room in London or Toronto or San Diego, a person with depression that hasn't budged for years is swallowing a measured dose of laboratory-made psilocybin under the gaze of two trained therapists. No shaman. No icaros. No jungle. Just a sofa, an eye mask, a curated playlist, and a molecule that — chemically speaking — is identical to the one inside a Psilocybe cubensis mushroom growing in a damp Oaxacan field. This is the version of psychedelics that's about to go mainstream. And if you're researching an ayahuasca retreat, a psilocybin ceremony, or any kind of plant-medicine experience for help with depression, addiction, or trauma, it's worth understanding what's actually being built in the pharmaceutical lane — because it changes the landscape you're choosing from. Compass Pathways became the first psilocybin-focused company to trade publicly on a major US exchange, and its CEO has been refreshingly blunt about one thing: they don't grow mushrooms. They synthesize the active compound in a lab. The reasoning is practical, not philosophical. Regulators trust standardized batches. Doctors want precise dosing. A 25-milligram capsule made in a controlled facility is easier to study than a handful of dried caps that might vary in potency by a factor of three. The FDA granted the company breakthrough therapy designation back in 2018 for treatment-resistant depression — the term for depression that hasn't responded to at least two rounds of conventional antidepressants. That designation doesn't mean approval. It means the agency agrees the unmet need is serious enough to fast-track the review process. Phase II trials are now running across roughly nine countries, testing different dose strengths to find the sweet spot before Phase III. The internal target is to have a legally prescribable psilocybin therapy on the market within the next couple of years. Whether they hit that timeline or not, the direction is clear: psilocybin is moving from the Schedule I list toward the prescription pad, one trial at a time. Here's where it gets interesting for anyone weighing a retreat. The clinical-trial version of a psilocybin session looks almost nothing like an Amazonian ayahuasca ceremony or a Mazatec velada. There's no group circle. No master plants in the traditional sense. No fasting protocols rooted in centuries of indigenous practice. The set is medical. The setting is medical. The framing is medical. That's not a criticism — it's a description. The clinical model is built to satisfy regulators and insurance companies, and it's designed for people who can't or won't travel to Peru, Costa Rica, or the Netherlands. For someone with severe depression who's been failed by SSRIs, having a covered, supervised psilocybin session in their own city might be the most accessible option they ever get. But it's a different experience from what plant-medicine retreats offer, and it answers a different set of questions. A retreat invites you into a tradition, a community, sometimes a worldview. A clinical session offers you a molecule, a sofa, and a follow-up appointment. Both can be profoundly helpful. They aren't the same thing. I get asked this almost every month. Someone reads an article about MDMA for PTSD or psilocybin for depression, sees the phrase “by 2026 or 2027,” and wonders whether they should just hang on a couple more years. My honest answer: it depends on how acute your situation is, what you're trying to address, and what kind of experience you're actually drawn to. If you're functional but stuck — patterns you can't break, grief you can't process, addictions that keep pulling you back — waiting for a clinical model that may or may not arrive on schedule is a real cost. Years of your life are not a small thing. Plenty of people who've sat in well-run ceremonies describe shifts that conventional therapy hadn't touched in a decade. The catch: the quality of the container matters enormously, and bad retreats absolutely exist. If you're in crisis — actively suicidal, in the grip of a substance dependency that's life-threatening, or managing a serious psychiatric condition — a retreat is usually not the right first move. Ceremonies are intense. They can surface material faster than you have support to handle. A reputable retreat will screen you out if you're in that zone, and if they don't, that itself is a red flag. The plant-medicine world isn't regulated the way the pharma world is. That's both its gift and its danger. The good retreats take screening seriously, run small groups, have medical staff on hand, and put as much emphasis on integration as they do on the ceremony itself. The bad ones take your money, hand you a cup, and send you back to the airport with a head full of unprocessed material and no support. A few things I'd want to know before sending money to any retreat center: For people specifically considering plant medicine for addiction, ibogaine deserves a separate conversation — it's a different molecule with a different risk profile (including real cardiac risk) and requires medical supervision that goes beyond what most ayahuasca retreats provide. Don't lump it in with mushrooms or ayahuasca just because they all fall under the “psychedelic” umbrella. The Compass CEO used the phrase “Cambrian explosion” to describe what's coming in the broader psychedelic and mental-health space. He's probably right. We're going to see prescription psilocybin, MDMA-assisted therapy, ketamine clinics on every other block, decriminalization measures in more cities, indigenous-led retreats fighting to protect their traditions, venture-backed startups trying to patent everything that isn't nailed down, and a long tail of underground practitioners doing what they've been doing for fifty years. The reader who benefits most from all this won't be the one who picks a side. It'll be the one who understands the differences — between a ceremony and a clinical session, between a master plant and a synthesized molecule, between a tradition with thousands of years behind it and a startup with a Series B. Both lanes can serve real people. Neither is the answer for everyone. If you've read this far, you're probably not researching idly. You're weighing something specific. For readers who want to take this further, a range of curated psychedelic and plant-medicine retreats can be browsed on our marketplace here — useful for getting a sense of what's actually out there before you commit to anything. Take your time. The molecule will still be there next month, and so will the vine.
Inside the Psilocybin Microdosing Boom: What Founders, Doctors, and Researchers Actually Say
Somewhere between the third espresso and the fourth Slack message, a quiet experiment is unfolding in the tech world. Founders, VCs, and operators — people who would happily debate Series A term sheets at midnight — are dropping crumb-sized amounts of psilocybin into their morning routine and reporting back like amateur neuroscientists. Welcome to the so-called shroom boom, where ayahuasca, psychedelics, addiction recovery conversations, and the older idea of master plants are colliding with the productivity industrial complex. It’s a strange moment. Magic mushrooms — the same fungi that defined a generation of 1960s counterculture — are now being microdosed before pitch meetings. Whether that’s a genuine evolution in human wellness or a tech-bro repackaging of an ancient sacrament depends on who you ask. So let’s actually ask. A microdose is small. Really small. Researchers like Dr. James Fadiman, who has spent decades documenting the practice, define it as roughly one-twentieth to one-tenth of a recreational dose — enough to nudge the nervous system, not enough to send you into the cosmos. You don’t hallucinate. You don’t see the walls breathe. Ideally, you barely notice anything other than feeling a touch more present. People microdose all sorts of substances: psilocybin mushrooms, LSD, occasionally cannabis, and in rarer cases sub-perceptual amounts of DMT or even ayahuasca tinctures. Psilocybin is by far the most popular because it’s organic, relatively forgiving, and — at the moment — culturally fashionable. Protocols vary. Some follow Fadiman’s one-day-on, two-days-off cycle. Others do two days on, five off. A few people just take it when they feel like it, which researchers tend to politely call “not a protocol.” And no, it’s not the same as sitting in a ceremony with a curandero and drinking a cup of brewed master plants for eight hours. A microdose is the opposite experience — quiet, undramatic, almost boring. That’s the point. The anecdotal case is consistent enough to be interesting. Founders describe sharper focus, less anxious chatter, a sense of being able to listen properly in conversations. One beverage entrepreneur in Florida told reporters that after he started microdosing, he found himself less reactive and more open — fewer doses of caffeine, fewer panicked spirals between meetings. A Los Angeles wellness founder calls her routine a “nano-dose,” about an eighth of a full dose, taken a few mornings a week. She says it dissolves anxiety the way a hot bath dissolves muscle tension. A former Canadian finance consultant turned psychedelic educator put it most bluntly: microdosing, she says, let her get three days of work done in one. She’s now built a small business around teaching others to do the same. You hear a few themes again and again from people who microdose seriously: That last one is interesting. Microdosers often say the effect compounds across the week, rather than living and dying inside the dose itself. Whether that’s real or a story they’re telling themselves is exactly where the science gets wobbly. Here’s the honest version. Macro-dose psilocybin research — full ceremonial doses given in clinical settings — is genuinely promising. There are well-designed trials showing meaningful effects on treatment-resistant depression, end-of-life anxiety, and addiction recovery, particularly for alcohol and nicotine dependence. That body of work is one of the reasons psychedelics, addiction, and mental-health treatment now share so much real estate in medical journals. Microdosing is a different story. The randomized, double-blind studies that do exist tend to show modest effects, much of which can be explained by expectation. As one Harvard-affiliated physician researcher has pointed out, almost everyone who microdoses believes it helps them, but the trials don’t cleanly confirm it. Creativity, focus, presence — these aren’t cholesterol levels. They’re slippery to measure. The gold-standard trial design doesn’t translate well to subjective wellness gains. That doesn’t mean microdosing is fake. It means we’re early. The psychedelic research renaissance has had perhaps two decades of serious momentum, and most of that funding has gone toward the more dramatic, easier-to-measure clinical applications. Microdosing science is still catching up. Under United States federal law, psilocybin is a Schedule I controlled substance. Possession is illegal. That’s the headline. The fine print is more interesting: Oregon allows supervised adult use through licensed service centers, Colorado has moved in a similar direction, and cities including Denver, San Francisco, Oakland, Seattle, and Minneapolis have decriminalized personal possession to varying degrees. Several state-level legalization efforts have stalled. Canada, meanwhile, is racing ahead with a patchwork of clinics, retreats, and brick-and-mortar mushroom shops operating in legal grey zones. So legality depends entirely on where you’re standing when you swallow the capsule. None of this is legal advice — please do your own homework based on your jurisdiction. As for safety, microdosing is generally considered lower-risk than full-dose use, but “lower risk” doesn’t mean “no risk.” A few honest caveats worth knowing: For a lot of people, microdosing isn’t the destination — it’s the doorway. Curious about psilocybin in small amounts, they eventually start reading about full-dose experiences, about ayahuasca, about the long-standing traditions of plant medicine and master plants in the Amazon and the Andes. That’s a meaningful step up in intensity, and it deserves a different kind of preparation. If you’re weighing a retreat — psilocybin, ayahuasca, San Pedro, or something else in the plant-medicine family — a few things are worth thinking about before the credit card comes out. Who runs the retreat? What lineage or training do the facilitators come from? What’s the medical screening process? What does integration support look like in the weeks after you fly home? Is there a real container around the experience, or is it essentially a vacation with a substance attached? The good retreats tend to ask you as many questions as you ask them. The questionable ones take your deposit before they’ve learned your last name. A retreat is not a productivity hack. It’s an experience that can reshape how you see your life, and the people guiding it matter enormously. There’s a strange double life happening in tech right now. Some founders talk openly about their psilocybin practice on podcasts. Others won’t mention it out loud, even with VCs they suspect are doing the same thing. The 2021 firing of an Iterable CEO who admitted to dosing LSD before a meeting still hangs in the air as a cautionary tale. That stigma is shifting, slowly. Investors are pouring money into psychedelic biotech. Cities and states are loosening laws. The conversation around psychedelics, addiction recovery, and mental health is moving from fringe to mainstream faster than almost anyone predicted ten years ago. Still, the most thoughtful people in this world tend to caution against treating mushrooms as a life hack. The traditions that have used these plants for centuries don’t talk about productivity. They talk about humility, listening, and being changed by something larger than yourself. Worth holding both ideas at once. If you’ve read this far, you’re probably not looking for a hot take. You’re trying to figure out whether any of this is for you. A few honest suggestions: For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. These are old medicines moving through a very new world, and the people who get the most out of them tend to be the ones who took their time getting in.
Ayahuasca Goes Global: What the Worldwide Boom Means for the Vine, the Cultures, and You
Twenty years ago, if you wanted to sit with ayahuasca, you flew to Iquitos or you knew someone who knew someone. Today there's a ceremony happening tonight, probably within driving distance of wherever you're reading this. That shift — from sacred regional medicine to global phenomenon — is the single biggest story in plant medicine right now. And almost nobody talks about it honestly. I want to walk you through what ayahuasca's globalization actually looks like in 2026: the legal patchwork, the Brazilian church tradition that most retreat-seekers have never heard of, the uncomfortable colonial questions baked into psychedelic tourism, and what all of this means if you're sitting at your laptop right now wondering whether to book a retreat. This isn't a hype piece. It's the conversation I wish someone had with me before my first ceremony. Ayahuasca isn't a Peruvian thing. Or a Brazilian thing. Or any single thing. It's a brew — usually Banisteriopsis caapi vine combined with a DMT-containing leaf like chacruna — used by dozens of distinct Indigenous Amazonian peoples for who-knows-how-many centuries. Each lineage has its own songs, its own dietary protocols, its own cosmology. Lumping them together is like saying all of Europe practices "European religion." What changed in the 20th century was the emergence of Brazilian ayahuasca churches: Santo Daime in the 1930s, Barquinha shortly after, and the União do Vegetal (UDV) in the 1960s. These groups braided ayahuasca use with Christian symbolism, African-Brazilian spiritual influences, and folk Catholicism. They built something genuinely new — a sacrament-based religious practice that travels well across borders. Brazil banned the brew briefly in 1985, then walked it back after the UDV requested a formal review. A working group spent two years visiting churches, interviewing leaders, reading the science. They concluded ayahuasca was a legitimate religious practice and lifted the ban for good. By 2010 the Brazilian government had reaffirmed the right of religious use under principles of religious freedom and protection of Indigenous and African-Brazilian cultural traditions. Heritage agencies began processes to recognize ayahuasca as intangible cultural patrimony. It's a remarkable arc — drug policy slowly giving way to cultural-heritage policy. Here's the part that surprises most people: there are two ayahuasca-using religious organizations operating legally in the United States. The UDV won a unanimous Supreme Court decision in 2006 protecting their sacramental use under the Religious Freedom Restoration Act. Santo Daime followed with a federal court win shortly after. Both organizations operate openly, ship the brew across state lines under religious exemption, and conduct ceremonies in cities you've heard of. That does NOT mean ayahuasca is generally legal in the U.S. The DMT in it is still Schedule I. The exemptions are narrow, granted to specific religious organizations after years of expensive litigation. Independent shamans, weekend ceremony groups, and most of the "retreat in a rented Airbnb" operations you see advertised on Instagram exist in a legal grey zone that's mostly tolerated until it isn't. People have been raided. People have done prison time. So when somebody asks me is ayahuasca legal where I live? — the honest answer is: probably not, with carve-outs that depend on the country, the state, the specific church, and the political weather. Europe has tightened considerably in recent years; the rate of arrests and prosecutions there has been climbing in a way that should give anyone pause. Brazil and Peru remain the most permissive. The U.S. sits somewhere in between, paradoxically more open than most of Europe because of its religious-freedom framework. The world ayahuasca diaspora — that's the term researchers use — has been gathering speed since the 1990s. People from the Global North fly to the Amazon, drop somewhere between $1,500 and $5,000 on a week-long retreat, drink the brew three to six times, and fly home. For many of them, including me on a first trip a long time ago, the experience is genuinely useful. For some, it's life-changing. For a small number, it's seriously destabilizing in ways the brochure didn't mention. But the broader picture is more complicated than the personal one. The boom has produced real consequences in source countries: None of this means you shouldn't go. It means you should go with eyes open. The most important single question to ask a prospective retreat: what is your relationship to the local community, and how do they benefit from your presence here? If the answer is vague or defensive, that tells you something. One of the reasons readers find articles like this one is that they're quietly considering plant medicine for something specific — addiction, depression, trauma, a stuck pattern that talk therapy hasn't budged. The research on ayahuasca for these conditions is genuinely promising. Small but well-designed studies have shown meaningful reductions in depression scores, improvements in PTSD symptoms, and substantial drops in substance use among ceremony participants. The mechanism appears to involve both the neurochemistry of DMT and the structured introspective process the ceremony provides. That said, ayahuasca is one of several so-called master plants in Amazonian tradition — others include tobacco (the strong jungle kind, not cigarettes), San Pedro, and various tree barks used in extended dietas. Calling them "master plants" reflects a worldview where the plant itself is the teacher and the ceremony is the classroom. Whether you take that literally or treat it as a useful metaphor, the framing matters. People who approach ayahuasca as a one-shot fix usually leave disappointed. People who approach it as the start of a longer relationship with their own healing tend to get more out of it. For addiction specifically, the picture is more nuanced than headlines suggest. Ibogaine has more dramatic acute effects on opioid withdrawal. Ayahuasca seems to work more slowly, through repeated exposure and the integration of insight over months. Neither is a magic bullet. Both work better when the person comes in already committed to changing something, with support waiting for them when they get home. If you've read this far, you're probably actually considering booking something. Here's what I tell friends who ask: Cost varies wildly. A modest Peruvian retreat run by a local family might run $1,200 for a week. A polished Western-facing operation with chefs and yoga decks can easily clear $5,000. Price is not a reliable proxy for safety or authenticity in either direction. The cheapest places sometimes cut corners on medical screening; the most expensive sometimes deliver a sanitized experience that's more spa than ceremony. The genie isn't going back in the bottle. Ayahuasca is going to keep spreading. The question is whether it spreads in ways that respect the source cultures and produce genuinely good outcomes for participants, or whether it gets ground down into another wellness commodity, sold next to cold plunges and breathwork classes. Both futures are still live possibilities. What I find quietly hopeful is the slow, unglamorous work happening on multiple fronts: legal advocacy for religious-use exemptions, conservation projects for caapi vine cultivation, ethical frameworks for benefit-sharing with Indigenous communities, integration networks for people coming back from ceremonies, and serious clinical research being done in partnership with — not extraction from — traditional knowledge holders. That work doesn't make headlines. It's how a real psychedelic culture gets built. If you're weighing a decision right now, take your time. Read more than one perspective. Talk to people who've gone, including the ones who had hard experiences. And if you want to compare reputable ayahuasca retreats with transparent intake processes, integration support, and clear ties to their host communities, a curated selection can be browsed on our marketplace here. The medicine has been around for centuries. It'll wait until you're ready.
Oregon's Psilocybin Law: What Legal Magic Mushrooms Actually Mean for You
When Oregon voters passed Measure 109, something shifted in the American psychedelic landscape that we're still living with the consequences of. Psilocybin — the active compound in so-called magic mushrooms — became legal for therapeutic use, with the state itself overseeing how it would be grown, distributed, and administered. No doctor's note required. No prescription pad. Just a framework, slowly being built, for adults to access psilocybin in a supervised setting. That was years ago now, and the rollout has been messier and more interesting than anyone predicted. If you're sitting in 2026 wondering whether Oregon's program is actually a path you can walk, or whether it's relevant to your own thinking about a psilocybin retreat, this is the honest version of where things stand and what it means. Let's get the basics out of the way. Measure 109 created a state-licensed program for the supervised use of psilocybin by adults. It did not make mushrooms legal to grow in your backyard, sell to your neighbor, or take recreationally. Possession outside the licensed framework is still illegal under Oregon law, though a separate ballot measure decriminalized small personal amounts to the lowest law-enforcement priority. The companion piece — the one most people miss — is that none of this changes federal law. Psilocybin remains a Schedule I substance at the federal level, which means the DEA still classifies it as having no accepted medical use. The state and the feds are essentially looking past each other on this, which is the same uneasy arrangement that's been propping up state cannabis programs for years. What you get inside Oregon is a service model. You show up at a licensed service center, you go through a preparation session with a licensed facilitator, you take a measured dose of psilocybin produced by a licensed manufacturer, and you stay there — often for six to eight hours — while a facilitator sits with you. Then there's an integration conversation afterward. It's not therapy in the clinical sense (facilitators aren't required to be therapists), and it's not a free-for-all either. The research story is what makes all of this more than a policy curiosity. Over the past decade, work out of Johns Hopkins, NYU, and a handful of other institutions has produced some of the most striking mental-health results in modern psychiatry — particularly for people who haven't responded to conventional antidepressants. Studies on treatment-resistant depression, end-of-life anxiety in cancer patients, and tobacco and alcohol addiction have all shown effects that, frankly, would be considered remarkable if they came from a pharmaceutical pill. A few things stand out in that literature. The effects tend to come from a small number of doses — sometimes just one or two — rather than daily medication. They seem to persist for months. And they appear to work through something psychologically meaningful, not just a chemical lever. People describe sessions that reframe how they relate to grief, fear, or the patterns they've been stuck in for years. None of this is a guarantee that a psilocybin session will fix what's wrong, and serious researchers are careful to say so. The data is promising; it isn't a finished story. But it's strong enough that ignoring psilocybin's potential, as a category of medicine, has gotten harder to defend. This is where people get confused, and it matters if you're trying to make a real decision. Oregon's service-center model is not a multi-day retreat in the traditional sense. You don't typically stay overnight. You don't typically join a group ceremony with songs and ritual. It's closer to an outpatient session — show up, sit with a facilitator, have your experience, go home (or to a hotel) once you're cleared to leave. Retreats, by contrast, usually involve several days of preparation, multiple ceremonies, group meals, and structured integration time. They draw on lineages — Mazatec, Amazonian, contemporary therapeutic — that shape how the medicine is offered. Some are run in jurisdictions where psilocybin is legal or unregulated (the Netherlands has long had a workaround using psilocybin truffles; Jamaica has hosted retreats for years). Others operate in the gray zones of various countries. Each model has trade-offs: Which one fits depends on what you're after. Someone working with end-of-life anxiety might want the medicalized, closer-to-home option. Someone exploring chronic depression or a long-standing stuck pattern might want the deeper container of a retreat. Neither is automatically better. Here's the part that surprises people. A single supervised psilocybin session in Oregon often runs anywhere from $1,500 to $3,500 once you factor in the preparation meeting, the dosing session, the facilitator's time, the product itself, and integration. Insurance doesn't cover it. That's not the program's fault — building this kind of infrastructure from scratch is expensive — but it has meant that the people who can access psilocybin legally in the U.S. tend to be the people who could already afford a flight to a retreat somewhere else. Retreats abroad range widely too. A short psilocybin retreat in the Netherlands can run $2,000 to $4,000 including lodging and meals. Longer programs with more ceremonies push higher. The famous Jamaica retreats have charged in the five-figure range for premium experiences. The point is, no path here is cheap, and the legal options haven't yet delivered the affordability that early advocates hoped for. If you're reading this because you're considering psilocybin for depression, anxiety, addiction, grief, or just a long stuck feeling that won't shift, a few questions are worth sitting with before you book anything. One thing I'd push back on, gently: the framing that psilocybin is a cure. The research is genuinely exciting, and people do have experiences that change their lives. But the substance is a doorway, not a destination. What you do in the weeks and months after — therapy, lifestyle change, the slow work of putting insights into practice — is where the real shift happens or doesn't. Colorado has since passed its own program with a somewhat different design. Other states have introduced bills, working groups, and pilot programs at various stages. The FDA has continued to grant Breakthrough Therapy designation to psilocybin-assisted treatment for major depression, which signals that the federal landscape is at least slowly moving. Clinical trials have multiplied. Insurance reimbursement is still mostly a fantasy, but there's chatter about pilot programs. The retreat world has also matured. There are more facilitators with serious training, more lineages openly teaching, more honest conversation about what can go wrong, and — importantly — more public reckoning with bad actors. The early years of this resurgence had a tendency to treat every charismatic guide as enlightened. That's softened into something more discerning, which is good for everyone. For readers ready to look at specific options, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whether you end up in Oregon, abroad, or simply continue researching for another year, the most important step is the one most people skip: getting clear, before you book anything, on what you're actually hoping the medicine will help you with.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Why Executives and Creatives Are Sitting in Ayahuasca Ceremonies
A few years ago, if you mentioned ayahuasca at a founder dinner in San Francisco or London, you'd get a nervous laugh and a subject change. Now? Somebody at the table has already been. Maybe two people. The conversation has shifted from “you did what?” to “who did you sit with, and would you recommend them?” Plant medicine has crossed a line in the professional world. Not into the mainstream, exactly — your accountant probably isn't booking a dieta in the Sacred Valley — but into a quieter, more curious middle ground. Senior people in tech, finance, design, and the creative industries are showing up at ayahuasca retreats and psilocybin retreats with a specific set of questions: am I burned out beyond repair? Why do I keep building the same problem? What am I avoiding? And, sometimes, the more practical: can this help me think again? This piece is for the reader who's noticed the trend and is wondering whether there's anything real underneath it — or whether it's just the next thing the productivity crowd is using to bypass their own feelings. The cliché answer is creativity. People say they want their edge back, they want to think laterally again, they want to break out of the spreadsheet brain that two decades of decision-making has welded into place. That's part of it. But spend any time with people who've actually done the work and you hear a different story underneath. What most of them are really chasing is relief. Relief from the low-grade depression that high performers learn to hide. Relief from the relationship patterns they keep re-enacting. Relief from a drinking habit that started as networking and turned into a problem. Relief from the dread of getting on another flight, another stage, another all-hands. Creativity is the socially acceptable wrapper. Healing is what's inside. And then there's the addiction question, which is where things get genuinely interesting. A growing number of professionals — and I mean the kind who run companies, not the kind who star in recovery memoirs — are looking at ayahuasca and ibogaine for issues with alcohol, cocaine, prescription benzos, and the more contemporary plague of compulsive screen and stimulant use. Plant medicine for addiction isn't a new idea in the Amazon. It's just newly visible to people who used to think recovery happened in church basements. The science is real, but it's also younger than the headlines suggest. Here's the honest version. What the research does not say: that any of this is a cure, that one ceremony will fix anything permanently, or that it's safe for everyone. Plenty of people have profound experiences and then slowly slide back into the same life they had before. The window closes. Whether anything changes long-term depends almost entirely on what happens in the months after. If you only know plant medicine through the Silicon Valley framing, it's worth pausing on what the traditions themselves call this work. In the upper Amazon, the brew is one of a wider family of master plants — tobacco (mapacho), bobinsana, ajo sacha, chuchuhuasi, chiric sanango, and others — each understood to teach something specific. Curanderos don't talk about neuroplasticity. They talk about cleaning, about diet, about the plants showing you what you need to see. You don't have to buy the cosmology to take it seriously. The point is that ayahuasca didn't arrive in the world as a productivity hack. It arrived as a discipline, with rules, with preparation, with sacrifices. The professionals I've seen get the most from ceremony are the ones who can hold both frames at once — the neuroscience and the older language — without collapsing one into the other. The ones who get the least, in my experience, treat the medicine like a software update. They show up, dose, expect output. The medicine, as the saying goes, has other ideas. If you're weighing whether to book an ayahuasca retreat, here's roughly what to expect from a serious one. (A non-serious one is something different and we'll get to that.) Costs vary widely. A reputable week-long ayahuasca retreat in Peru or Costa Rica generally runs somewhere between $1,500 and $4,500, depending on facilities, lineage of the curanderos, and group size. Cheaper than that, ask hard questions. More expensive than that, ask different hard questions. I'd be doing you a disservice to write a piece like this without naming what can go wrong. Psychiatric risk is real. People with personal or family histories of psychosis, schizophrenia, or bipolar I should not be doing this work, full stop. Ayahuasca can also surface unprocessed trauma in a way that's overwhelming if there's no integration support. Some retreats are excellent at holding that. Some are not. Medication interactions are real. Ayahuasca contains MAO inhibitors, which can interact dangerously with SSRIs, SNRIs, stimulants, and a long list of other substances. A proper retreat requires a medication washout period under medical supervision. A sketchy one waves it off. Facilitator quality varies enormously. The plant medicine space has its share of self-appointed shamans, charismatic frauds, and outright predators. Sexual abuse in ceremony settings has been documented and is more common than the industry likes to admit. Vet thoroughly. Ask for references from past participants. Look for transparent lineage and long-running operations rather than someone who learned to pour medicine on a six-month course. And then there's the most underrated risk: the post-retreat crash. You come home glowing, convinced everything is different, and then the inbox is still the inbox, the marriage is still the marriage, and three months later you can't quite remember what you saw. Without integration, the insights evaporate. Plan for that part before you book. The honest answer is: sometimes, and not the way you'd expect. People come back with fewer breakthrough product ideas than they expected and more clarity about which projects they should never have started. They get less of a creative high and more of a willingness to have the conversation they've been avoiding. They report finishing things they'd been stuck on for years, less because they had a stroke of genius and more because they finally stopped flinching from the work. The founders I've spoken to who got real value from ceremony almost all say the same thing: it didn't make them better at their job. It made them a different person, and that person did the job differently. Sometimes that person quit the job entirely. Sometimes they stayed and finally led the team like a human being. Either way, it's not really a productivity tool. It's a mirror. If you're considering this for yourself, take your time. Read more than one perspective. Talk to people who've sat in ceremony with the facilitators you're considering. Treat your preparation as seriously as you'd treat any other significant decision in your life — because that's what it is. For readers who want to take this further, a curated range of ayahuasca and plant medicine retreats can be browsed on our marketplace here. The trend isn't really about executives chasing the next biohack. It's about a generation of people who built impressive lives and then quietly realised that none of it touched the thing underneath. The medicine doesn't promise to fix that. It just, occasionally, helps you finally look at it.
The Ayahuasca Vine Explained: Banisteriopsis Caapi, Effects, and What Science Knows
Most people who book an ayahuasca retreat have only a fuzzy idea of what's actually in the cup. They know the word. They've heard the stories — the visions, the purge, the long night in the maloca. What they often don't know is that the brew is a partnership between two plants, and one of them — the vine itself — is doing quiet, essential work that makes the whole experience possible. That vine is Banisteriopsis caapi, and it deserves a proper introduction. If you're considering an ayahuasca ceremony, understanding the caapi vine isn't optional trivia. It tells you why the brew exists at all, why facilitators handle it with such care, and why the legal status of plant medicine is so tangled depending on where you stand. Let's actually look at the plant. The scientific name is Banisteriopsis caapi. Across the Amazon, it goes by other names too — yagé, caapi, the vine of the soul, sometimes just “the vine.” It belongs to the Malpighiaceae family, a botanical group that emerged in the Amazon basin somewhere around 1.25 million years ago, when plant diversity in the rainforest exploded. So the lineage is old. Genuinely old. Older than our species by an embarrassing margin. Visually, it's a beast. The vine can stretch up to thirty meters through the canopy, twisting around host trees like cabling. It puts out small white or pale-pink flowers, usually in January, and from a distance it's hard to distinguish from a few of its botanical cousins. The part that matters for ceremony is the woody stem — pounded, simmered for hours, sometimes for a full day, often combined with another plant to make the brew people travel thousands of miles to drink. Here's where most introductions skip the interesting bit. The caapi vine, on its own, is not the psychedelic. Drink a strong caapi-only tea and you'll feel something — a heaviness, a kind of dreamy intoxication, some nausea, maybe shadowy monochrome visuals that look like smoke or silhouettes. But you won't have the kaleidoscopic, full-architecture visions that ayahuasca is famous for. Not even close. The active compounds in caapi are a group of harmala alkaloids — primarily harmine, harmaline, and tetrahydroharmine. Concentrations vary wildly between vines, anywhere from a fraction of a percent up to eight or nine percent depending on the strain and growing conditions. What these alkaloids do in the body is the clever part: they're monoamine oxidase inhibitors, or MAOIs. They temporarily switch off an enzyme called monoamine oxidase that your gut and liver use to break down certain compounds. One of the compounds your body usually destroys on contact? DMT. Swallow pure DMT and nothing happens — your gut chews it up before it reaches the brain. But take caapi first, and the doorway stays open. Add a DMT-containing plant like Psychotria viridis (chacruna) to the brew, and suddenly DMT becomes orally active. That's the chemistry behind the visions. The vine isn't the psychedelic. The vine is what makes the psychedelic possible. Early researchers were so taken with harmine they once called it “telepathine,” genuinely believing it was responsible for the shared visions ceremony participants sometimes report. We've since walked that back, but the name tells you something about how strange the first scientific encounters with this plant were. The caapi vine is geographically picky. It grows naturally only in the Amazon basin, mainly across: That's it. No native population in Africa, in Asia, in North America. This is partly why most traditional ayahuasca retreat centers cluster in countries like Peru and Brazil — proximity to the source, proximity to the lineages that have worked with the plant the longest. You can grow caapi in greenhouses elsewhere, and people do, but the cultural and ecological context stays anchored in the rainforest. Interestingly, archaeological evidence suggests the vine was being traded long distances even a thousand years ago. A shamanic pouch found in Bolivia, dated to around 1,000 years old, contained traces of both harmine and DMT. Hair samples from mummies in northern Chile's Atacama Desert — a place caapi cannot grow — also tested positive for harmine. Trade networks were moving this plant across the continent well before anyone in Europe had heard of it. This is where things get genuinely murky, and where I'd urge anyone thinking about plant medicine to slow down and pay attention. The legality of caapi versus the legality of the finished brew are two very different questions. In the United States, the caapi vine itself is legal to possess. Harmine and harmaline aren't scheduled. But the moment you combine caapi with a DMT-containing plant to make ayahuasca, you're in possession of a Schedule I substance under federal law. The notable exception came in 2006, when the Supreme Court ruled that members of the União do Vegetal (UDV) — a Brazilian-rooted religion that uses the brew as a sacrament — were exempt under the Religious Freedom Restoration Act. A similar exemption later extended to certain Santo Daime congregations. For most people, though, the brew remains illegal stateside. In Australia and Canada, harmala alkaloids are controlled substances, but the vine itself sits in an ambiguous legal zone — not explicitly banned, not explicitly permitted, and frequently decided case-by-case in court. In much of the Amazon — Peru, Brazil, Bolivia, Ecuador — the brew is recognized as a legitimate cultural and religious practice and is legal. That's the practical reason retreat tourism flows south. If you're researching where to do this work, legality should be one of your first questions, not your last. A retreat operating in a country where the brew is openly sanctioned is a different proposition from one operating in a legal grey zone where everyone — facilitators included — could face problems if something goes wrong. Nobody knows exactly how long indigenous Amazonian communities have been working with ayahuasca. Estimates range from several hundred to several thousand years. Some researchers trace its emergence to the Tukano region in the Colombian Amazon. Others argue for older origins further south. The truth is the lineage predates written records, and most of what we know comes from oral tradition combined with the occasional archaeological clue. The first written accounts came from Jesuit missionaries who started pushing into the Amazon in the 17th century. Predictably, they described the brew in horrified terms — diabolical, infernal, the work of the devil. Their reports tell us more about the missionaries than about the medicine. Westerners didn't actually start drinking it themselves until the 1800s, when explorers and naturalists in the Amazon began documenting the experience firsthand. What's often glossed over in retreat marketing is the diversity of traditional uses. The Piaroa people of Venezuela, for example, use caapi as a hunger suppressant, a stimulant, and a hunting aid — they say it sharpens vision. Other communities use it primarily for healing, for divination, for communicating with what they describe as the spirits of the forest. The vine is considered a teacher in its own right — a “master plant” with its own intelligence and its own lessons. That framing matters. It's not a recreational substance in those traditions. It's a relationship. Ayahuasca tourism, in the form most Westerners encounter it, is a late-20th-century phenomenon. It's grown rapidly since the 1990s, with ceremonies now happening in Costa Rica, Portugal, Spain, the Netherlands, and increasingly in private, underground settings worldwide. People come for different reasons — depression, trauma, addiction recovery, grief, spiritual curiosity, midlife disorientation. The brew doesn't care about your reasons. It tends to show you what's there. If you've only read marketing copy, you'd be forgiven for thinking ayahuasca is a kind of cosmic vision quest with optional vomiting. The real picture is messier and, frankly, more interesting. The full ceremony experience typically lasts six to eight hours — far longer than smoked DMT, which is closer to fifteen or twenty minutes. The harmala alkaloids from the caapi vine give the journey its dreamlike quality, slowing it down, deepening it, sometimes producing what people describe as the sense of being “held” by something older than themselves. The DMT contributes the visual architecture, the geometric complexity, the sense of meeting presences or entities. Then there's the physical side: nausea, sweating, the famous purge (which is sometimes vomiting, sometimes crying, sometimes both at once, sometimes neither). Body load can be intense. Some people lie down for most of the night. Others sit up wrapped in a blanket, watching the inside of their own mind unfold. Each ceremony is different, even within the same retreat, even within the same person across two nights. For people specifically considering plant medicine for addiction or depression, the emerging research is cautiously promising — studies have observed reductions in substance use and depressive symptoms after ceremony, particularly when combined with serious integration work afterward. But it's not a magic bullet. The people I've spoken with who got the most from their experiences treated the ceremony as the beginning of work, not the end of it. Knowing the plant doesn't tell you whether a retreat is right for you. It does, though, give you a foundation for asking better questions. Where is the caapi sourced? Who prepares the brew, and how? Does the facilitator have a real lineage, or did they take a weekend course? What's the screening process — do they check your medications, your medical history, your mental health background? Anyone who skips that screening is cutting a corner you don't want cut. The vine is ancient and the medicine is powerful. Both deserve respect, and so do you. If after all this you find yourself genuinely curious about where the work might lead, a thoughtfully curated selection of ayahuasca retreats can be browsed on our marketplace here — not as a sales pitch, just as a starting point for the kind of careful comparison this decision actually deserves.
Ibogaine Treatment One Year Later: What Long-Term Recovery Actually Looks Like
Most of what gets written about ibogaine focuses on the 36 hours of the experience itself. The flood dose. The visions. The interruption of withdrawal that addiction researchers keep calling, with cautious astonishment, unlike anything else they've measured. But here's the thing nobody really prepares you for: the actual work of ibogaine recovery happens in the year after you leave the clinic, not the night you take it. I've sat with people who flew home from Mexico convinced they were cured, and watched a few of them quietly relapse within ninety days. I've also met people who described their session as underwhelming — even disappointing — and then noticed, six months later, that they hadn't picked up in over half a year. The shape of ibogaine recovery is strange. It's not a straight line. This piece is for anyone weighing whether a psychedelic plant-medicine retreat involving iboga is the right move, and especially for anyone wondering what the long tail of that decision actually looks like. Ibogaine is the principal alkaloid in the root bark of Tabernanthe iboga, a shrub native to West Central Africa where it's been used ceremonially by the Bwiti tradition for generations. In the clinical context that's emerged in Mexico, Costa Rica, Portugal, and a handful of other places where it sits in legal gray zones, it's used primarily for opioid dependence. The reason is mechanistic: a single flood dose appears to reset opioid receptors in a way that eliminates acute withdrawal symptoms for most people within hours. That part is real. The science has caught up enough that even cautious addiction researchers acknowledge ibogaine does something genuinely unusual. But here's where misunderstandings start. Ibogaine doesn't cure addiction. It removes the physical scaffolding — the dope sickness, the bone-deep craving spike — that makes early sobriety physically unbearable. What it gives you is a window. What you do with that window is everything. People often describe the experience itself as more like watching a documentary about your own life than tripping. There's a long review phase where memories surface unbidden, often the ones you've spent years anesthetizing. It can be brutal. It can also be the first time in a decade you've sat with certain feelings sober. Master plants tend to work this way — they don't hand you answers, they hand you the material you've been avoiding. The first weeks after a flood dose can feel uncanny. Cravings that ruled your life are just… absent. People describe waking up and noticing the silence where the obsession used to be. Energy returns. Sleep gets weird for a while, then normalizes. Many people report a lingering afterglow — a softness, an emotional openness — that can last anywhere from a few weeks to a few months. This is the honeymoon, and it's the most dangerous period of ibogaine recovery. Not because of the medicine itself, but because the absence of craving creates a false sense of permanence. You start thinking I'm done. That was the thing. I beat it. And then somewhere around week eight or twelve, real life sneaks back in — a fight with a parent, a layoff, a Tuesday night with nothing to do — and the brain remembers its old shortcut. What separates people who hold onto sobriety from people who don't, in my observation, comes down to a few specific things: This is the stretch nobody talks about because it's not photogenic. The afterglow fades. You start having normal human bad days again. Some people experience a kind of grief around month five — a mourning for the substance, or for the version of themselves who used it, or for the years they lost. This is normal. It's also where a lot of people quietly fall off, because they assumed the medicine was supposed to make them feel good forever. What's actually happening here is more interesting. The neurological reset gave you a clean baseline. Now your brain is doing the slow work of building new pathways — what a real life feels like, what reward looks like without the substance, what intimacy is when you're not numbed. That kind of rewiring takes months. There's emerging evidence that ibogaine promotes neuroplasticity for a sustained window after the experience, which is part of why integration during this stretch matters so much. The window is open. What you put in it shapes what closes around. People who do well during this phase tend to be doing some combination of trauma-focused therapy (somatic work, EMDR, internal family systems), regular movement, structured sleep, and some form of contemplative practice. They've often connected with others who've done iboga and can compare notes without judgment. They're not white-knuckling — they're rebuilding. A year out, the people I've stayed in touch with describe something I find hard to summarize cleanly. It's not that they're cured of wanting. It's that wanting has lost its authority. Cravings, when they come, feel more like weather than command — something that passes through rather than something that runs the show. The other shift is harder to name. Most describe a kind of self-knowledge that they didn't have before, a feeling of having genuinely met themselves during the experience and having to keep living with what they saw. Some find this clarifying. Some find it uncomfortable. Almost no one describes it as nothing. A few patterns from the one-year check-ins I've collected: If you're researching ibogaine seriously, the choice of provider is the single most important decision you'll make — more important than location, price, or amenities. Ibogaine carries genuine cardiac risk, and reputable providers screen rigorously: ECG, liver panel, full medication and substance history, sometimes a stress test. If a retreat doesn't ask you for medical records before accepting you, that's not a retreat — it's a liability. Things to ask before you book: Cost varies wildly — anywhere from around $5,000 to over $15,000 for a week-long program — and the price doesn't reliably track quality. Some of the best clinics aren't the most expensive. Some of the most expensive are essentially wellness theatre with a flood dose tacked on. Ibogaine isn't right for everyone. People with cardiac conditions, certain liver issues, or specific medication combinations face real risk. People without solid support to return to often struggle more than they would have with a different approach. And there are people for whom traditional recovery pathways — twelve-step, medication-assisted treatment, long-term residential — are genuinely better fits. Plant medicine isn't morally superior to other forms of addiction recovery. It's a tool, and the right tool depends on the job. I'd also gently push back on the idea that ibogaine is a single-session miracle. Some people benefit from a booster session at six or twelve months. Some need ongoing work with other modalities. The narrative of one ceremony fixing everything makes good copy and poor reality. Master plants tend to ask more of you than they give, at least at first. If you've read this far, you're probably someone who's already done a lot of the harder work — the noticing, the questioning, the quiet decision that something has to change. That counts for more than most retreats will tell you. If iboga or another plant-medicine approach feels like it might be part of the answer, a range of vetted ibogaine and broader psychedelic retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly, with good information and people around you who'll still be there in a year — because a year is when the real story of any of this gets written.
Oregon Psilocybin Law: What's Legal, What Isn't, and Why It Matters for Retreat-Seekers
A few years back, a small herbal shop in Portland made the kind of headlines that confuse the hell out of anyone trying to understand where psychedelics actually stand in the United States. People lined up around the block. They filled out questionnaires. They walked out with bags of psilocybin mushrooms — varieties with names like Penis Envy and Albino Golden Teacher — paying somewhere around $85 to $95 for seven grams. The shop framed itself as Oregon's first licensed psychedelic dispensary. It wasn't. Not even close. And the gap between what was happening on that sidewalk and what Oregon's psilocybin law actually permits is exactly the kind of confusion that trips up people researching plant medicine, master plants, and psychedelic retreats. If you're weighing whether to spend real money on a retreat, you need to understand this landscape clearly — because the difference between a legal therapeutic container and an unregulated transaction has real consequences for your safety, your wallet, and your healing. Oregon passed Measure 109 — the Oregon Psilocybin Services Act — back in November 2020. It was the first state-level psilocybin law of its kind in the country, and it was a genuine milestone for psychedelic-assisted recovery. But the measure didn't do what a lot of casual readers assume it did. It did not decriminalize mushrooms. It did not legalize recreational sale. It did not turn psilocybin into something you can pick up alongside your kombucha. What it created was a tightly regulated framework for supervised therapeutic use. Under Measure 109, psilocybin can only be consumed at a licensed service center, in the presence of a licensed facilitator, by someone who has gone through a preparation session. There is no take-home model. There is no retail counter. There is no path — present or planned — for buying mushrooms over the counter and walking out with them. Sam Chapman, who runs the Healing Advocacy Fund, put it about as plainly as anyone can: nothing in Measure 109, and nothing in any other Oregon law, permits the retail sale of psilocybin mushrooms. Not today, not in the future as the law is currently written. The state's licensed services exist because Oregonians dealing with depression, anxiety, and addiction stand to benefit from psilocybin — but only when the therapy is delivered safely, with screening, integration, and a trained guide. The Shroom House situation is a useful case study in what happens when commercial momentum runs ahead of regulation. Customers were asked to join a so-called "Shroom House Society," show two forms of ID, prove they were over 21, and fill out a questionnaire that asked about mental health history. From a distance, that paperwork looks vaguely clinical. Up close, it's a loyalty card with extra steps. A reporter who walked in was apparently buying within five minutes of finishing the form. A former employee eventually went to local news and said management had told staff the shop was the first medically sanctioned psychedelic retailer in the state. It wasn't. The Oregon Health Authority hadn't even started issuing facilitator and service-center licenses yet. The shop was operating in a legal vacuum that didn't actually exist — psilocybin is still a Schedule I substance under federal law, and at the time, no Oregon entity had authority to sell it commercially under state law either. The honest takeaway here isn't outrage. It's the recognition that wherever there's genuine therapeutic demand and unclear regulation, opportunists will find the seam. For anyone researching psychedelics seriously — especially anyone hoping to use them for addiction or depression — knowing the difference between an above-board therapeutic container and a guy with a storefront is essential. Compare the Portland storefront with what an actual psychedelic retreat involves and the contrast becomes obvious. Whether we're talking about psilocybin services in Oregon, ayahuasca ceremonies in the Peruvian Amazon, ibogaine in Mexico, or San Pedro in the Andes, the legitimate end of this world shares a common shape: None of that is what happens when you buy mushrooms over a counter and take them home. That's not a retreat. That's not therapy. That's a transaction, and any framing that suggests otherwise is doing the medicine — and the people it might help — a disservice. The honest answer is: increasingly, the evidence says yes — but the conditions matter enormously. Clinical research on psilocybin for alcohol use disorder, ibogaine for opioid dependence, and ayahuasca for various substance and behavioral addictions has been quietly accumulating for two decades now. The trial results aren't fringe anymore. Johns Hopkins, NYU, Imperial College London — serious institutions are publishing serious data on psychedelic-assisted recovery, and the early signal is that these compounds can interrupt patterns that years of conventional treatment couldn't budge. That said, master plants and synthetic psychedelics aren't magic. They're powerful tools that work best when held inside a real therapeutic process. Someone in active addiction who buys mushrooms at a storefront and dips in alone is not running the same intervention as someone going through a screened, prepared, facilitated session. The substance might be identical. The outcome rarely is. Set and setting — that old Leary phrase — turns out to be more than a slogan. It's most of the medicine. This is why the legal framework Oregon is building, slow and frustrating as it can feel, actually matters. A regulated facilitator model creates the conditions under which psilocybin's therapeutic potential can show up reliably. A storefront free-for-all creates the conditions under which people get hurt and the whole movement gets a black eye. Here's the practical takeaway. If you're someone quietly considering plant medicine — for a stuck depression, a trauma you can't seem to metabolize, an addiction that has outlasted every other intervention — the Portland story is a useful warning. The space is filling up with operators whose understanding of safety ranges from excellent to nonexistent. Marketing language and clinical legitimacy are not the same thing. A few things worth checking before you commit money or travel: The psychedelic-assisted recovery field is in a strange adolescent phase right now. The laws are catching up unevenly. The science is racing ahead. And in the gap between the two, both genuine healing centers and outright opportunists are setting up shop. Your job as a researcher — and a potential participant — is to tell them apart. If you've read this far and want to keep exploring legitimate options, a range of vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.
Vancouver's Magic Mushroom Dispensaries: Civil Disobedience or Legalization Strategy?
Walk down certain blocks of East Vancouver and you'll spot something that probably shouldn't exist under federal law: storefronts openly selling psilocybin. Chocolates, capsules, dried caps in glass jars. No back rooms, no whispered passwords. Just a counter, a price list, and a clerk who'll happily explain the difference between a microdose and what they call a “heroic” one. It's strange. It's a little brazen. And if you've been following the slow, uneven march of psychedelics from underground curiosity to clinical research darling, it's also very, very familiar. Because this exact playbook — open a shop, dare the authorities to shut you down, force the conversation — is how Canada ended up legalizing cannabis. Now a handful of activists are running the same experiment with magic mushrooms, and the rest of us get to watch in real time. Psilocybin is a controlled substance under Canadian federal law. Selling it is illegal. And yet, in Vancouver, a small but growing cluster of dispensaries does exactly that — out in the open, with signage, social media accounts, and customer reviews. The most visible operator is Dana Larsen, a longtime drug-policy activist who runs the Medicinal Mushroom Dispensary out of the same space as his Coca Leaf Café. He started selling psilocybin chocolates and capsules to walk-in customers a few years back, and he's been pretty transparent about his strategy: keep selling, get noticed, force the government to either crack down hard or move toward regulation. So far the government has done neither, which is its own kind of answer. Other shops have followed. Some opened during the pandemic to make up for lost revenue from cannabis or other businesses. A few are run by people who genuinely believe psilocybin should be available for therapeutic use and are tired of waiting for Ottawa to catch up. The Vancouver Police have said mushroom prosecutions aren't a top priority. City Hall has sent some sternly worded letters. The shops are still open. Here's the thing about Vancouver: this city has been a testing ground for drug-policy civil disobedience for decades. Illegal cannabis dispensaries operated openly there from at least 2015, with the city eventually creating a municipal licensing system — even though selling weed was still federally illegal at the time. Three years later, Canada legalized recreational cannabis nationwide. Was that legalization the direct result of grey-market shops? Probably not entirely. But the shops normalized the conversation. They made it impossible for politicians to pretend the demand wasn't there. They gave the public a chance to see, for years, that the sky didn't fall. By the time Parliament got around to writing legislation, the cultural battle was largely over. The mushroom dispensary owners are betting the same dynamic will play out again. The bet isn't crazy. Psilocybin research is moving fast — clinical trials at major universities, Health Canada granting individual exemptions for people with terminal illness or treatment-resistant depression, and a steady drip of mainstream media coverage that treats the molecule as medicine rather than menace. The legal frame is wobbling. Someone was always going to push. Let's pause on the medical claim, because it matters. There's now a real body of clinical evidence suggesting that psilocybin — typically administered in larger, supervised doses alongside psychotherapy — can produce meaningful and sometimes lasting reductions in depression and anxiety, including for people who haven't responded to standard treatments. It's also being studied for addiction, end-of-life distress, and a handful of other conditions where the conventional pharmaceutical toolkit has been underwhelming. This isn't fringe stuff anymore. It's published in peer-reviewed journals. It's drawing real money into psychedelic biotech. A psychedelic-focused exchange-traded fund launched on a Canadian exchange a few years ago, which is roughly the most boring possible signal that a thing has gone mainstream. Microdosing — taking sub-perceptual amounts on a regular schedule — is a different story. The popular case for it has run well ahead of the data. Some researchers find modest mood and creativity effects; others find that most of what people report is placebo. If you're considering microdosing for a specific mental health issue, the honest answer is: the jury's still out, and a properly supervised larger-dose session may have far stronger evidence behind it. Even with the shops operating openly, psilocybin remains illegal to sell or possess in Canada outside narrow exemptions. Health Canada does grant individual access through its Special Access Program, and there's a Section 56 exemption pathway, but both processes are slow, paperwork-heavy, and require specific medical circumstances. A not-for-profit called TheraPsil has spent years helping patients — especially those facing terminal diagnoses — navigate the bureaucracy. Many people give up and turn to grey-market shops or underground guides instead. In the United States, the picture is more fragmented. Federally, psilocybin is Schedule I. But Oregon has rolled out a regulated psilocybin services program, Colorado has decriminalized personal possession and is building out its own framework, and a growing list of cities — Denver, Oakland, Seattle, Detroit, several others — have effectively deprioritized enforcement. None of this makes it legal to buy mushrooms at a shop the way Vancouverites can. But the legal terrain is shifting fast enough that anything written about it has a short shelf life. If you've read this far, there's a decent chance you're not just curious about Canadian drug policy. You're weighing whether a psychedelic experience — mushrooms, ayahuasca, something else — might actually help with something specific. Depression that won't budge. A drinking problem. Grief. A sense that you've been on autopilot for years and can't find the off switch. A few honest things to consider before you walk into any dispensary or book any retreat: Vancouver's mushroom shops won't be the last act in this story. Whether they get raided, regulated, or quietly absorbed into a future legal framework, they've already done some of the work activists wanted them to do — they've made psilocybin visible, debatable, and increasingly unavoidable as a policy question. Other cities will follow. Some governments will move quickly; others will dig in. For individuals trying to figure out whether plant medicine has a real role in their own life, the better path is usually slower than walking into a shop. It involves reading widely, talking to people who've done the work, screening yourself for real medical risks, and choosing a setting with trained facilitators and a clear integration plan. Retreats — especially ones in jurisdictions where the practice is legal or traditionally protected — remain the most evidence-supported way most people access these experiences. If you're starting that research, a range of curated psilocybin and plant-medicine retreats can be explored on our marketplace here. The Vancouver dispensaries are an interesting symptom of where the culture is going. They're probably not where your own story should start.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
